<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358266</url>
  </required_header>
  <id_info>
    <org_study_id>32-007</org_study_id>
    <nct_id>NCT01358266</nct_id>
  </id_info>
  <brief_title>Study Assessing Double-masked Uveitis Treatment</brief_title>
  <acronym>SAKURA</acronym>
  <official_title>A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of intravitreal injections
      of DE-109 ophthalmic solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5</measure>
    <time_frame>Day1 (Baseline) and Month 5 (Day150)</time_frame>
    <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification
Vitreous Haze Scale Description VH score 0 = No inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)</measure>
    <time_frame>Day1/Baseline and Day150/Month 5</time_frame>
    <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)</measure>
    <time_frame>Day1/Baseline and Day150/Month 5</time_frame>
    <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)</measure>
    <time_frame>Day1/Baseline and Day180/Month 6</time_frame>
    <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification
Vitreous Haze Scale Description VH score 0 = No inflammation</description>
  </other_outcome>
  <other_outcome>
    <measure>VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)</measure>
    <time_frame>Day1/Baseline and Day180/Month 6</time_frame>
    <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
  </other_outcome>
  <other_outcome>
    <measure>VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)</measure>
    <time_frame>Day1/Baseline and Day180/Month 6</time_frame>
    <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">592</enrollment>
  <condition>Uveitis; Posterior, Disorder</condition>
  <arm_group>
    <arm_group_label>Ophthalmic solution low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ophthalmic solution medium dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ophthalmic solution high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-109 44 ug</intervention_name>
    <description>Low dose</description>
    <arm_group_label>Ophthalmic solution low dose</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-109 440 ug</intervention_name>
    <description>Medium dose</description>
    <arm_group_label>Ophthalmic solution medium dose</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-109 880 ug</intervention_name>
    <description>High dose</description>
    <arm_group_label>Ophthalmic solution high dose</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of active uveitis

          -  18 years of age or older

          -  Sign informed consent

          -  Meet best corrected ETDRS visual acuity

        Exclusion Criteria:

          -  Uveitis of infectious etiology

          -  Suspected/confirmed central nervous system or ocular lymphoma

          -  Primary diagnosis of anterior uveitis

          -  Uncontrolled glaucoma

          -  Use of topical oculary medication

          -  Implanted device

          -  Significant ocular disease

          -  Lens/media opacities or obscured ocular media

          -  Intraocular surgery or treatments

          -  Capsulotomy

          -  Ocular or periocular infection

          -  Pupillary dilation

          -  History of herpetic infection

          -  Toxoplasmosis or toxoplasmosis scar

          -  Ocular malignancy

          -  Allergy or hypersensitivity to study drug

          -  Participation in other uveitis trial within 30 days

          -  Monoclonal antibody treatment or biologic therapy

          -  Any systemic condition/infection

          -  Immunosuppressive therapy or immunocompromised

          -  Malignancy remission

          -  Females who are pregnant or lactating and females not using adequate contraceptives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abu Abraham, MD</last_name>
    <role>Study Director</role>
    <affiliation>Santen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florencio Varela</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olivos</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pilar</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Americana</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Araraquara</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Londrina</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bhubaneshwar</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madurai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Noida</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petaẖ Tiqwa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrevieja</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Dominican Republic</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <results_first_submitted>May 8, 2018</results_first_submitted>
  <results_first_submitted_qc>June 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2019</results_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects who entered open-label period are defined as subjects who received at least one open-label injection during the open-label treatment period (Month 6 to Month 12, exclude Amendment 2 subjects), or those who had entered the open-label retreatment period (Month 12 to Month 24) with or without any PRN injections.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DE-109 44 μg</title>
          <description>SAKURA Study 1 &amp; Study 2 (Amendment #2) Double-Masked Treatment Period Injection on Day 1, Month 2, Month 4 Double-Masked PRN Treatment Period May receive up to 3 injections PRN from Month 6 through Month 10 SAKURA Study 1 &amp; Study 2 (Amendments #3 and #4) Injection on Day 1, Month 2, Month 4 SAKURA Study 2 (Amendment #5) Double-Masked Treatment Period Injection on Day 1, Month 2, Month 4</description>
        </group>
        <group group_id="P2">
          <title>DE-109 440 μg</title>
          <description>SAKURA Study 1 &amp; Study 2 (Amendment #2) Double-Masked Treatment Period Injection on Day 1, Month 2, Month 4 Double-Masked PRN Treatment Period May receive up to 3 injections PRN from Month 6 through Month 10 SAKURA Study 1 &amp; Study 2 (Amendments #3 and #4) Injection on Day 1, Month 2, Month 4 SAKURA Study 2 (Amendment #5) Double-Masked Treatment Period Injection on Day 1, Month 2, Month 4</description>
        </group>
        <group group_id="P3">
          <title>DE-109 880 μg</title>
          <description>SAKURA Study 1 &amp; Study 2 (Amendment #2) Double-Masked Treatment Period Injection on Day 1, Month 2, Month 4 Double-Masked PRN Treatment Period May receive up to 3 injections PRN from Month 6 through Month 10 SAKURA Study 1 &amp; Study 2 (Amendments #3 and #4) Injection on Day 1, Month 2, Month 4
Open-Label Treatment Period Injection on Month 6, Month 8, Month 10 Open-Label Re-Treatment Period May receive up to 6 injections PRN through Month 22 SAKURA Study 2 (Amendment #5) Double-Masked Treatment Period Injection on Day 1, Month 2, Month 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Masked Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="208"/>
                <participants group_id="P3" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DE-109 44 µg</title>
          <description>Double Masked Phase Low Dose 44 µg Open Label Phase High Dose 880 µg</description>
        </group>
        <group group_id="B2">
          <title>DE-109 440 µg</title>
          <description>Double Masked Phase Medium Dose 440 µg Open Label Phase High Dose 880 µg</description>
        </group>
        <group group_id="B3">
          <title>DE-109 880 µg</title>
          <description>Double Masked Phase High Dose 880 µg Open Label Phase High Dose 880 µg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="208"/>
            <count group_id="B2" value="208"/>
            <count group_id="B3" value="176"/>
            <count group_id="B4" value="592"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="532"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5</title>
        <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification
Vitreous Haze Scale Description VH score 0 = No inflammation</description>
        <time_frame>Day1 (Baseline) and Month 5 (Day150)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DE-109 44 µg</title>
            <description>Low Dose DE-109 44 µg</description>
          </group>
          <group group_id="O2">
            <title>DE-109 440 µg</title>
            <description>Medium Dose DE-109 440 µg</description>
          </group>
          <group group_id="O3">
            <title>DE-109 880 µg</title>
            <description>High Dose DE-109 880 µg</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5</title>
          <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification
Vitreous Haze Scale Description VH score 0 = No inflammation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)</title>
        <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
        <time_frame>Day1/Baseline and Day150/Month 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DE-109 44 µg</title>
            <description>Low Dose DE-109 44 µg</description>
          </group>
          <group group_id="O2">
            <title>DE-109 440 µg</title>
            <description>Medium Dose DE-109 440 µg</description>
          </group>
          <group group_id="O3">
            <title>DE-109 880 µg</title>
            <description>High Dose DE-109 880 µg</description>
          </group>
        </group_list>
        <measure>
          <title>VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)</title>
          <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)</title>
        <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)</description>
        <time_frame>Day1/Baseline and Day150/Month 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DE-109 44 µg</title>
            <description>Low Dose DE-109 44 µg</description>
          </group>
          <group group_id="O2">
            <title>DE-109 440 µg</title>
            <description>Medium Dose DE-109 440 µg</description>
          </group>
          <group group_id="O3">
            <title>DE-109 880 µg</title>
            <description>High Dose DE-109 880 µg</description>
          </group>
        </group_list>
        <measure>
          <title>VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)</title>
          <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)</title>
        <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification
Vitreous Haze Scale Description VH score 0 = No inflammation</description>
        <time_frame>Day1/Baseline and Day180/Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DE-109 44 µg</title>
            <description>Low Dose DE-109 44 µg</description>
          </group>
          <group group_id="O2">
            <title>DE-109 440 µg</title>
            <description>Medium Dose DE-109 440 µg</description>
          </group>
          <group group_id="O3">
            <title>DE-109 880 µg</title>
            <description>High Dose DE-109 880 µg</description>
          </group>
        </group_list>
        <measure>
          <title>VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)</title>
          <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification
Vitreous Haze Scale Description VH score 0 = No inflammation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)</title>
        <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
        <time_frame>Day1/Baseline and Day180/Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DE-109 44 µg</title>
            <description>Low Dose DE-109 44 µg</description>
          </group>
          <group group_id="O2">
            <title>DE-109 440 µg</title>
            <description>Medium Dose DE-109 440 µg</description>
          </group>
          <group group_id="O3">
            <title>DE-109 880 µg</title>
            <description>High Dose DE-109 880 µg</description>
          </group>
        </group_list>
        <measure>
          <title>VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)</title>
          <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)</title>
        <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
        <time_frame>Day1/Baseline and Day180/Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DE-109 44 µg</title>
            <description>Low Dose DE-109 44 µg</description>
          </group>
          <group group_id="O2">
            <title>DE-109 440 µg</title>
            <description>Medium Dose DE-109 440 µg</description>
          </group>
          <group group_id="O3">
            <title>DE-109 880 µg</title>
            <description>High Dose DE-109 880 µg</description>
          </group>
        </group_list>
        <measure>
          <title>VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)</title>
          <description>At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+
Moderate blurring of the optic nerve head
Marked blurring of the optic nerve head
Optic Nerve head not visible</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events – begin capturing once the first treatment is given. Per Schedule of Events through study completion, up to 24 months.</time_frame>
      <desc>Any subject with multiple AEs of one system organ class is counted only once for that class.
Subjects are classified by actual treatment received. AEs summaries were done with the Safety Population (N=590) defined as all randomized subjects who received at least one study treatment.1 subject was randomized to the 44 μg dose group but received 880 μg at Month 2
1subject was randomized to the 44 μg dose group but received 880 μg at Month 4 both subjects are reflected in the 880/880 μg group.</desc>
      <group_list>
        <group group_id="E1">
          <title>DE-109 44 µg - Double Masked</title>
          <description>Double Masked Phase Low Dose 44 µg</description>
        </group>
        <group group_id="E2">
          <title>DE-109 440 µg - Double Masked</title>
          <description>Double Masked Phase Medium Dose 440 µg</description>
        </group>
        <group group_id="E3">
          <title>DE-109 880 µg - Double Masked</title>
          <description>Double Masked Phase High Dose 880 µg</description>
        </group>
        <group group_id="E4">
          <title>DE-109 880 µg - Open-Label</title>
          <description>Open-label Phase High Dose 880 µg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Choroiditis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Non-infectious endophthalmitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Intermediate uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Optic atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Optic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Corneal deposits</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Corneal epithelium defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Ocular vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Retinal infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medication residue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Eye infection toxoplasmal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cataract traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="205"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Fibrin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Intraocular pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>1 subject 44 µg dose group died • a 63-year-old male who suffered a stroke on Day 54 (11 Sep 2012) of study participation.This subject died on Study Day 55 (12 Sep 2012). This SAE was reported as severe, and not related to the study medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Optic Neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="205"/>
                <counts group_id="E3" subjects_affected="148" subjects_at_risk="178"/>
                <counts group_id="E4" subjects_affected="210" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="207"/>
                <counts group_id="E2" events="46" subjects_affected="32" subjects_at_risk="205"/>
                <counts group_id="E3" events="51" subjects_affected="30" subjects_at_risk="178"/>
                <counts group_id="E4" events="48" subjects_affected="31" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="207"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E3" events="42" subjects_affected="29" subjects_at_risk="178"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="32" subjects_affected="22" subjects_at_risk="207"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E3" events="33" subjects_affected="26" subjects_at_risk="178"/>
                <counts group_id="E4" events="33" subjects_affected="24" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="205"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="178"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Intermediate uveitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="178"/>
                <counts group_id="E4" events="14" subjects_affected="9" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="205"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="178"/>
                <counts group_id="E4" events="33" subjects_affected="32" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="205"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Choroiditis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="178"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="205"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Vitreous opacities</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="205"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="50" subjects_affected="34" subjects_at_risk="207"/>
                <counts group_id="E2" events="62" subjects_affected="34" subjects_at_risk="205"/>
                <counts group_id="E3" events="64" subjects_affected="43" subjects_at_risk="178"/>
                <counts group_id="E4" events="62" subjects_affected="44" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Santen Inc.</organization>
      <phone>+1-415-268-9100</phone>
      <email>clinicaltrials@santen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

